Denali Therapeutics Stock Quote DNLI - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

30.91

Bid

27.94

Ask

30.90

Volume

1,997,843

30.65 Day's Range 31.24

14.56 52 Week Range 32.132

Market Cap

4.425B

Previous Close

31.05

Open

30.94

Last Trade

30.9

Last Trade Time

Financial Volume

$ 61,742,631

VWAP

30.9046

Average Volume (3m)

987,489

Shares Outstanding

143,165,264

Dividend Yield

PE Ratio

-30.47

Earnings Per Share (EPS)

-1.01

Revenue

330.53M

Net Profit

-145.22M

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates ... Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.denalitherapeutics.com

Headquarters

Wilmington, Delaware, USA

Founded

Denali Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker DNLI. The last closing price for Denali Therapeutics was $31.05. Over the last year, Denali Therapeutics shares have traded in a share price range of $ 14.56 to $ 32.132.

Denali Therapeutics currently has 143,165,264 shares outstanding. The market capitalization of Denali Therapeutics is $4.45 billion. Denali Therapeutics has a price to earnings ratio (PE ratio) of -30.47.

Overall Flow

Bullish

Net Premium

297k

Calls / Puts

200.00%

Buys / Sells

50.00%

OTM / ITM

50.00%

Sweeps Ratio

0.00%

Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)

Recent successful meeting with the FDA provides path to file for accelerated approval and subsequent conversion to full approvalPlan to submit biologics license application (BLA) early in 2025...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	2.91	10.3928571429	28	32.132	28	1465751	30.71970569	CS
4	6.8	28.2040647034	24.11	32.132	23.85	1014606	27.54603827	CS
12	7.9	34.3328987397	23.01	32.132	19.74	987489	24.4456952	CS
26	10.57	51.9665683382	20.34	32.132	14.56	1077379	21.4786597	CS
52	8.82	39.9275690358	22.09	32.132	14.56	1075176	20.47608595	CS
156	-20.23	-39.5580758702	51.14	56.08	14.56	791624	26.29909928	CS
260	12.78	70.4908990623	18.13	93.94	12.39	706995	32.06084831	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
BNZIBanzai International Inc	$ 5.645 (96.01%)	61.39M
ZJYLJin Medical International Ltd	$ 3.975 (50.00%)	1.24M
ANEBAnebulo Pharmaceuticals Inc	$ 2.9001 (39.43%)	78.85k
XPONExpion360 Inc	$ 0.081 (39.18%)	1.46B
AENTAlliance Entertainment Holding Corporation	$ 2.74 (34.31%)	4.23M
GSIWGarden Stage Ltd	$ 1.34 (-82.89%)	26.44M
CRBPCorbus Pharmaceuticals Holdings Inc	$ 19.51 (-62.26%)	12.29M
LGCBLinkage Global Inc	$ 0.4183 (-57.70%)	2.16M
BFIBurgerFi International Inc	$ 0.0855 (-42.27%)	15.05M
SKYESkye Bioscience Inc	$ 3.17 (-42.26%)	5.14M
XPONExpion360 Inc	$ 0.081 (39.18%)	1.46B
NVDANVIDIA Corporation	$ 116.00 (-1.59%)	378.16M
AAPLApple Inc	$ 228.20 (-0.29%)	320.24M
INTCIntel Corporation	$ 21.84 (3.31%)	261.68M
VERBVerb Technology Company Inc	$ 0.0742 (33.45%)	178.65M